Veriti Management LLC Buys 590 Shares of Incyte Co. (NASDAQ:INCY)
Veriti Management LLC Buys 590 Shares of Incyte Co. (NASDAQ:INCY)
Veriti Management LLC raised its holdings in shares of Incyte Co. (NASDAQ:INCY – Get Rating) by 4.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,630 shares of the biopharmaceutical company's stock after buying an additional 590 shares during the period. Veriti Management LLC's holdings in Incyte were worth $1,111,000 at the end of the most recent quarter.
據Incell Co.最近向美國證券交易委員會披露的信息,Veriti Management LLC在第二季度將其持有的Incell Co.(納斯達克代碼:INCY-GET)的股票持有量提高了4.2%。該基金持有這家生物製藥公司14,630股股票,在此期間又購買了590股。截至最近一個季度末,Veriti Management LLC持有的Incell股份價值1,111,000美元。
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Parkside Financial Bank & Trust increased its holdings in Incyte by 91.0% during the first quarter. Parkside Financial Bank & Trust now owns 447 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 213 shares during the last quarter. Ellevest Inc. increased its stake in shares of Incyte by 210.1% in the first quarter. Ellevest Inc. now owns 673 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 456 shares in the last quarter. CKW Financial Group increased its stake in shares of Incyte by 33.3% in the first quarter. CKW Financial Group now owns 800 shares of the biopharmaceutical company's stock worth $64,000 after purchasing an additional 200 shares in the last quarter. Newfound Research LLC purchased a new stake in shares of Incyte in the second quarter worth $67,000. Finally, Tobam increased its stake in shares of Incyte by 53.3% in the first quarter. Tobam now owns 892 shares of the biopharmaceutical company's stock worth $71,000 after purchasing an additional 310 shares in the last quarter. 94.74% of the stock is owned by hedge funds and other institutional investors.
其他對衝基金和其他機構投資者也增持或減持了該公司的股份。Parkside Financial Bank&Trust在第一季度增持了Incell 91.0%的股份。Parkside Financial Bank&Trust現在持有這家生物製藥公司447股股票,價值3.6萬美元,上個季度又購買了213股。Ellevest Inc.在第一季度增持了Incell的股份210.1%。Ellevest Inc.現在持有這家生物製藥公司673股股票,價值53,000美元,上個季度又購買了456股。長江基建金融集團第一季增持Incell股份33.3%長江基建金融集團現在持有這家生物製藥公司800股股票,價值6.4萬美元,該集團在上個季度又購買了200股。新發現研究有限責任公司在第二季度購買了價值6.7萬美元的Incell新股。最後,Tobam在第一季度增持了Incell的股份53.3%。託巴姆現在持有這家生物製藥公司892股股票,價值71,000美元,上個季度又購買了310股。94.74%的股票由對衝基金和其他機構投資者持有。
Insider Transactions at Incyte
Incell的內幕交易
In other news, insider Thomas Tray sold 1,564 shares of the firm's stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $83.13, for a total value of $130,015.32. Following the completion of the sale, the insider now owns 17,702 shares in the company, valued at approximately $1,471,567.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Thomas Tray sold 1,564 shares of the firm's stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $83.13, for a total value of $130,015.32. Following the completion of the sale, the insider now owns 17,702 shares in the company, valued at approximately $1,471,567.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Vijay K. Iyengar sold 5,787 shares of the firm's stock in a transaction dated Thursday, July 7th. The stock was sold at an average price of $79.38, for a total transaction of $459,372.06. Following the completion of the sale, the executive vice president now owns 40,313 shares of the company's stock, valued at approximately $3,200,045.94. The disclosure for this sale can be found here. Company insiders own 17.50% of the company's stock.
其他消息方面,內部人士託馬斯·特雷在7月22日星期五的一筆交易中出售了1,564股該公司股票。這些股票的平均價格為83.13美元,總價值為130,015.32美元。出售完成後,這位內部人士現在擁有該公司17,702股股票,價值約1,471,567.26美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過此超鏈接。其他消息方面,內部人士託馬斯·特雷在7月22日星期五的一筆交易中出售了1,564股該公司股票。這些股票的平均價格為83.13美元,總價值為130,015.32美元。出售完成後,這位內部人士現在擁有該公司17,702股股票,價值約1,471,567.26美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過此超鏈接。此外,執行副總裁Vijay K.Iyengar在一筆日期為7月7日星期四的交易中出售了5787股該公司股票。該股以79.38美元的平均價格出售,總成交金額為459,372.06美元。出售完成後,執行副總裁總裁現在持有該公司40,313股股票,價值約3,200,045.94美元。關於這次銷售的披露可以找到這裏。公司內部人士持有該公司17.50%的股份。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Incyte Price Performance
Incell價格表現
INCY stock opened at $66.18 on Tuesday. Incyte Co. has a 52 week low of $61.91 and a 52 week high of $84.86. The company has a quick ratio of 3.85, a current ratio of 3.91 and a debt-to-equity ratio of 0.01. The company has a fifty day simple moving average of $73.08 and a two-hundred day simple moving average of $75.34. The firm has a market capitalization of $14.72 billion, a P/E ratio of 15.57, a price-to-earnings-growth ratio of 1.09 and a beta of 0.66.
Incy股價週二開盤報66.18美元。Incell Co.跌至61.91美元的52周低點和84.86美元的52周高點。該公司的速動比率為3.85,流動比率為3.91,債務權益比率為0.01。該公司的50日簡單移動均線切入位為73.08美元,200日簡單移動均線切入位為75.34美元。該公司的市值為147.2億美元,市盈率為15.57倍,市盈率為1.09倍,貝塔係數為0.66。
Incyte (NASDAQ:INCY – Get Rating) last released its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.85 EPS for the quarter, beating the consensus estimate of $0.61 by $0.24. Incyte had a net margin of 28.46% and a return on equity of 13.02%. The business had revenue of $911.40 million during the quarter, compared to analyst estimates of $818.25 million. During the same quarter last year, the business earned $0.65 earnings per share. Incyte's quarterly revenue was up 29.1% compared to the same quarter last year. Analysts anticipate that Incyte Co. will post 2.45 earnings per share for the current fiscal year.
納斯達克(Incy-Get Rating)最近一次發佈季度收益數據是在8月2日(星期二)。這家生物製藥公司公佈本季度每股收益為0.85美元,比普遍預期的0.61美元高出0.24美元。Incell的淨利潤率為28.46%,股本回報率為13.02%。該業務本季度營收為9.114億美元,而分析師預期為8.1825億美元。去年同一季度,該業務每股收益為0.65美元。與去年同期相比,Incell的季度收入增長了29.1%。分析師預計,Incell Co.本財年每股收益將達到2.45歐元。
About Incyte
關於Incell
(Get Rating)
(獲取評級)
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.
Incell Corporation是一家生物製藥公司,專注於美國和國際上專利療法的發現、開發和商業化。該公司提供Jakafi,一種治療骨髓纖維化和真性紅細胞增多症的藥物;PEMAZYRE,一種成纖維細胞生長因子受體激酶抑制劑,在各種液體和固體腫瘤類型中起致癌作用;以及Iclusig,一種治療慢性髓細胞白血病和費城染色體陽性的急性淋巴細胞白血病的激酶抑制劑。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Incyte (INCY)
- MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
- MO Money: Why Altria Group Stock is Rallying
- Is the Market Overreacting with Shopify Stock?
- Fed Raises Rates: 3 Stocks to Watch Newmont Mining, Walmart, AMC
- Three Consumer Stocks That Could Outperform In Q4
- 免費獲取StockNews.com關於Incell的研究報告(INCY)
- MarketBeat Podcast,3只股票關注紐蒙特礦業、沃爾瑪、AMC
- Mo Money:奧馳亞集團股價為何上漲
- 市場是否對Shopify Stock反應過度?
- 美聯儲加息:3只股票關注紐蒙特礦業、沃爾瑪、AMC
- 三隻可能在第四季度表現優異的消費類股
Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY – Get Rating).
想看看其他對衝基金持有INCY的什麼嗎?訪問HoldingsChannel.com獲取Incell Co.(納斯達克代碼:Incy-Get Rating)的最新13F申報文件和內幕交易信息。
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.
接受Incell Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Incell和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。